In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Outbreak of campylobacter food-poisoning in Northern Ireland

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Outbreak of campylobacter food-poisoning in Northern Ireland

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages B. Ekinci, A.Y. Coban, A. Birinci, B. Durupinar,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

Genital Chlamydia trachomatis infections

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Potential risk factors for infection with Candida spp

Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Structure of grepafloxacin relative to activity and safety profile

Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Laboratory diagnosis and biosafety issues of biological warfare agents

CMI editorial report 2011 Clinical Microbiology and Infection

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Clinical and microbiological characteristics of Nocardiosis including those caused by emerging Nocardia species in Taiwan, 1998–2008 C.-K. Tan, C.-C.

Uncommon opportunistic fungi: new nosocomial threats

Elements of design: the knowledge on which we build

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Advisory group on Home-based and Outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy D. Nathwani, J.-J.

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

Pathogenesis of catheter-related infections: lessons for new designs

Update on antifungal resistance in Aspergillus and Candida

Community-acquired pneumonia: epidemiologic and clinical consideration

Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece A. Spiliopoulou, S. Vamvakopoulou, C. Bartzavali, G.

Abstracts cont. Clinical Microbiology and Infection

Abstracts cont. Clinical Microbiology and Infection

Training in infectious diseases and tropical medicine in Britain

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

A. Norberg, C.E. Nord, B. Evengård Clinical Microbiology and Infection

Brita Bruun, Henrik Westh, Jørgen Stenderup

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study R. Goering, C.-E. Nord, R.

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Typing of Clostridium difficile

J.A. Pérez-Molina, F. Fernández Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Localized Mycobacterium avium complex infection in a patient on HAART

The future of diagnostic bacteriology

Presentation transcript:

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore, K.L. Oakley, D.W. Denning Clinical Microbiology and Infection Volume 7, Issue 1, Pages 11-16 (January 2001) DOI: 10.1046/j.1469-0691.2001.00158.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 The relationship between MIC and MFC values for Candida albicans (n = 42) [A] and non-albicans species (n = 63)[B] against LY303366. Clinical Microbiology and Infection 2001 7, 11-16DOI: (10.1046/j.1469-0691.2001.00158.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 The relationship between MIC and MFC values for Candida albicans (n = 42) [A] and non-albicans species (n = 63) [B] against amphotericin B. Clinical Microbiology and Infection 2001 7, 11-16DOI: (10.1046/j.1469-0691.2001.00158.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions